Pharmacyclics data positive, says JMP Securities

June 19, 2013

JMP Securities believes that new data on Pharmacyclics' ibrutinib in Waldenstrom’s Macroglobulinemia more than justifies its breakthrough therapy designation in this indication. The firm continues to expect the drug to receive FDA approval later this year, and it keeps an Outperform rating on the stock.